Pushing MYC inhibition closer to the clinic
Credit: VHIO VHIO-born spin-off Peptomyc S.L. has developed and preclinically validated mini-protein MYC inhibitor as effective and tolerable against notoriously difficult-to-treat lung cancer subtype Successful...












